MM120 · program
Lysergide D-tartrate (MM120 / LSD) for Generalized anxiety disorder
- Breakthrough Therapy
Indications for MM120: Generalized anxiety disorder · Phase 3 Attention-deficit/hyperactivity disorder · Discontinued Major depressive disorder · Phase 3 Post-traumatic stress disorder · Phase 3
MM120 (DT120) for generalized anxiety disorder — lead program. FDA Breakthrough Therapy granted 7 Mar 2024 on the Phase 2b dose-finding study (NCT05407064; 100 ug gave -7.7 HAM-A vs placebo at Week 12, Cohen's d 0.81). Two pivotal Phase 3 GAD studies underway: Voyage (NCT06741228) and Panorama (NCT06809595), both active, primary completion 2026. The same compound is also Phase 3 for MDD (Emerge, NCT06941844).
Development timeline
- FDA Breakthrough Therapy Designation (GAD); positive 12-week durability data from the Phase 2b study.↗
Clinical trials in Generalized anxiety disorder
NCT06809595PanoramaPhase 3Activen=245
Phase 3 Study of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06741228VoyagePhase 3Activen=214
Phase 3 Study of Oral DT120 vs Placebo in Generalized Anxiety Disorder (Voyage)
NCT05407064Phase 2Completedn=198
Phase 2b Dose-Finding Study of MM120 for Anxiety Symptoms
metprimaryHAM-A change at Week 12 (100 ug vs placebo) — -7.7 points (Cohen's d 0.81) (<0.003)
Clinical response 65%, remission 48% at Week 12.
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| DT120 orally disintegrating tablet (ODT)Orally disintegrating tablet (ODT) using Catalent Zydis fast-dissolve technology Proprietary orally disintegrating tablet of lysergide (LSD) D-tartrate; single administration; designed for faster absorption and onset | Oral | Single dose | — |
| MM120 oral (Phase 2b) Single oral dose; 25, 50, 100, or 200 µg freebase-equivalent studied in Phase 2b GAD; 100 µg selected as optimal for pivotal trials | Oral | Single dose | — |
Mechanism of action
LSD acts across serotonin receptor subtypes; the company describes MM120 as a 5-HT2A partial agonist (IUPHAR classifies LSD as a full 5-HT2A agonist). Antidepressant effects attributed primarily to 5-HT2A agonism.
| Target | Action | Affinity |
|---|---|---|
| 5-HT2AprimaryHTR2A | Partial agonist | pKi 9.4ⓘ |
| 5-HT1AHTR1A | Agonist | pKi 9ⓘ |
| 5-HT2CHTR2C | Agonist | pKi 8.2ⓘ |
← Full MM120 compound page (identity, identifiers, all indications)
Sources
- DT120 ODT — LSD Therapy for Depression and Anxiety — Definium Therapeutics
- First patient dosed in Voyage Phase 3 — MindMed / Definium
- clinicaltrials.gov — ClinicalTrials.gov
- ir.mindmed.co — Reference
- Lysergide (LSD), Ligand 17 — IUPHAR/BPS
- MindMed FDA Breakthrough + Phase 2b durability (GAD) — MindMed / Business Wire
- Panorama (NCT06809595) — ClinicalTrials.gov
- Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial — JAMA / PMC
- Voyage (NCT06741228) — ClinicalTrials.gov